MX2021013516A - Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares. - Google Patents

Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares.

Info

Publication number
MX2021013516A
MX2021013516A MX2021013516A MX2021013516A MX2021013516A MX 2021013516 A MX2021013516 A MX 2021013516A MX 2021013516 A MX2021013516 A MX 2021013516A MX 2021013516 A MX2021013516 A MX 2021013516A MX 2021013516 A MX2021013516 A MX 2021013516A
Authority
MX
Mexico
Prior art keywords
oxymetazoline
compositions
methods
ocular disorders
treating ocular
Prior art date
Application number
MX2021013516A
Other languages
English (en)
Inventor
Tina Devries
David Jacobs
Original Assignee
Rvl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rvl Pharmaceuticals Inc filed Critical Rvl Pharmaceuticals Inc
Publication of MX2021013516A publication Critical patent/MX2021013516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está dirigida a composiciones que comprenden oximetazolina y métodos para estabilizar composiciones de oximetazolina para almacenamiento a largo plazo. La presente invención también está dirigida a composiciones que comprenden oximetazolina y métodos para tratar diversos trastornos oculares relacionados con párpados caídos, tales como ptosis, en un sujeto que comprende administrar al sujeto composiciones que comprenden oximetazolina.
MX2021013516A 2019-05-06 2020-05-05 Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares. MX2021013516A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
PCT/US2020/031425 WO2020227260A1 (en) 2019-05-06 2020-05-05 Oxymetazoline compositions and methods for treating ocular disorders

Publications (1)

Publication Number Publication Date
MX2021013516A true MX2021013516A (es) 2022-01-24

Family

ID=72750169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013516A MX2021013516A (es) 2019-05-06 2020-05-05 Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares.

Country Status (17)

Country Link
US (11) US10799481B1 (es)
EP (1) EP3965737A1 (es)
JP (2) JP7141420B2 (es)
KR (3) KR102410503B1 (es)
CN (2) CN117045596A (es)
AU (1) AU2020268329A1 (es)
BR (1) BR112021022404A2 (es)
CA (1) CA3139443A1 (es)
CL (1) CL2021002918A1 (es)
CO (1) CO2021015265A2 (es)
IL (1) IL287831A (es)
MA (1) MA55895A (es)
MX (1) MX2021013516A (es)
PE (1) PE20220384A1 (es)
SG (1) SG11202112272TA (es)
WO (1) WO2020227260A1 (es)
ZA (1) ZA202108950B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
AU2007227091B2 (en) 2006-03-17 2013-02-07 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
AU2007243334A1 (en) 2006-04-26 2007-11-08 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling
US8466203B2 (en) * 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
US20090281156A1 (en) * 2007-12-21 2009-11-12 Schering-Plough Healthcare Products, Inc, Enhancing photostabilization of oxymetazoline
SI2262506T1 (sl) * 2008-03-11 2014-07-31 Alcon Research, Ltd. Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo
EP2437602A4 (en) * 2009-06-05 2014-02-19 Aciex Therapeutics Inc OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
AU2011327785A1 (en) * 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
AU2011336449B2 (en) 2010-12-03 2016-07-07 Epi Health, Llc Pharmaceutical cream compositions comprising oxymetazoline
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2013177594A2 (en) 2012-05-25 2013-11-28 Xlear, Inc. Xylitol-based anti-mucosal compositions and related methods and compositions
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
EP3047712B1 (en) 2013-09-18 2021-04-21 Mycronic AB Method, system and device for handling pallets in a smt system
ES2796871T3 (es) 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
WO2017132410A1 (en) 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant

Also Published As

Publication number Publication date
WO2020227260A1 (en) 2020-11-12
MA55895A (fr) 2022-03-16
US11103482B2 (en) 2021-08-31
US20220273621A1 (en) 2022-09-01
KR20220084264A (ko) 2022-06-21
EP3965737A1 (en) 2022-03-16
US20210015795A1 (en) 2021-01-21
KR102663319B1 (ko) 2024-05-03
AU2020268329A1 (en) 2022-01-06
US10799481B1 (en) 2020-10-13
JP2021191802A (ja) 2021-12-16
US20210137889A1 (en) 2021-05-13
KR102410503B1 (ko) 2022-06-17
US20240033250A1 (en) 2024-02-01
KR20200128629A (ko) 2020-11-16
US20210023222A1 (en) 2021-01-28
US20220257566A1 (en) 2022-08-18
IL287831A (en) 2022-01-01
CN111888326B (zh) 2023-07-21
JP2020183373A (ja) 2020-11-12
PE20220384A1 (es) 2022-03-18
CN117045596A (zh) 2023-11-14
US20200353083A1 (en) 2020-11-12
US11324722B2 (en) 2022-05-10
US11701343B2 (en) 2023-07-18
US20210386711A1 (en) 2021-12-16
BR112021022404A2 (pt) 2022-01-18
US11541036B2 (en) 2023-01-03
US10940138B2 (en) 2021-03-09
JP7141420B2 (ja) 2022-09-22
SG11202112272TA (en) 2021-12-30
CL2021002918A1 (es) 2022-08-19
CO2021015265A2 (es) 2022-02-28
US11311515B2 (en) 2022-04-26
US20210212992A1 (en) 2021-07-15
CN111888326A (zh) 2020-11-06
CA3139443A1 (en) 2020-11-12
ZA202108950B (en) 2023-10-25
US10814001B1 (en) 2020-10-27
KR20240060580A (ko) 2024-05-08
US10898573B1 (en) 2021-01-26
US20230355587A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
ZA202108950B (en) Oxymetazoline compositions and methods for treating ocular disorders
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
WO2016172712A3 (en) Ophthalmic composition
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
WO2016183424A8 (en) Light adjustable intraocular lenses using upconverting nanoparticles and near infrared (nir) light
TW201613588A (en) Ophthalmic composition
MX2018014868A (es) Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2018010788A (es) Composicion oftalmologica.
MX2019011784A (es) Compuestos de aril ciclopropil-amino-isoquinolinil amida.
WO2018218009A3 (en) CAPILLARY TREATMENT COMPOSITIONS, METHODS AND KITS FOR TREATING HAIR
EP4302734A3 (en) Ocular delivery systems and methods
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
EP3870170A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
MX2019002019A (es) Compuestos de beta-amino-isoquinolinil amida.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2021013447A (es) Composiciones y procedimientos para el tratamiento de enfermedades oculares.
CL2019002839A1 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2023002113A (es) Composicion que contiene dioxido de cloro y metodos para su uso.